<DOC>
	<DOC>NCT01491945</DOC>
	<brief_summary>The purpose of this trial is to determine if the Ventana Fenestrated Stent Graft System is safe and effective for the endovascular repair of juxtarenal or pararenal aortic aneurysms.</brief_summary>
	<brief_title>Safety and Effectiveness Trial of the Ventana Fenestrated Stent Graft System</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
	<criteria>Male or female at least 18 years old; Informed consent understood and signed and patient agrees to all followup visits; Have aortic aneurysm with maximum diameter ≥5.5cm, or between 4.5 and 5.5cm and rapidly expanding (&gt;0.5cm in six months), or &gt;50% larger than the normal aortic diameter Anatomically eligible for the Bifurcated System per the FDAapproved indications for use (IFU) and for the Fenestrated Stent Graft System: Adequate iliac/femoral access compatible with the required delivery systems Nonaneurysmal infrarenal aortic neck &lt;15mm in length; Most caudal renal artery to aortoiliac bifurcation length ≥70mm SMA to aortoiliac bifurcation length ≥90mm; Proximal nonaneurysmal aortic neck below the SMA with: diameter 18 to 34 mm; length ≥15 mm; angle ≤60° to the aneurysm sac; Angle ≤60° (clock face) between the SMA and CA Renal arteries both distal to the SMA by ≤35mm, within 30mm of each other axially, with 4 to 8mm lumen diameter, and with clock face angle of 90° to 210° to each other .Common iliac artery distal fixation site with: distal fixation length ≥15 mm; ability to preserve at least one hypogastric artery; diameter ≥10 mm and ≤23 mm; angle ≤90° to the aortic bifurcation. The Endologix Fenestrated Proximal Extension Stent must have the ability to overlap the bifurcated stent graft by at least 3cm. Aortic diameter at the most caudal renal artery of 18 to 36mm Life expectancy &lt;2 years as judged by the investigator; Psychiatric or other condition that may interfere with the study; Participating in the enrollment or 30day followup phase of another clinical study; Known allergy to any device component; Coagulopathy or uncontrolled bleeding disorder; Contraindication to contrast media or anticoagulants; Ruptured, leaking, or mycotic aneurysm; Aortic dissection Serum creatinine (SCr) level &gt;2.0 mg/dL; Traumatic vascular injury; Active systemic or localized groin infection; Connective tissue disease (e.g., Marfan's Syndrome); Recent (within prior three months) cerebrovascular accident or myocardial infarction; Prior renal transplant; Length of either renal artery to be stented &lt;13mm; Significant occlusive disease of either renal artery (&gt;70% stenosis); An essential accessory renal artery; Indispensable inferior mesenteric artery; Aneurysmal disease of the descending thoracic aorta; Clinically significant mural thrombus circumferentially in the suprarenal segment; Prior iliac artery stent implanted that may interfere with delivery system introduction; Unsuitable vascular anatomy; Pregnancy (female patient of childbearing potential only) Existing renal stent; Preplanned need for concomitant procedure (e.g. surgical conduit for vascular access, hypogastric artery embolization/coil, renal artery angioplasty)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Abdominal aortic aneurysm</keyword>
	<keyword>Renal stent</keyword>
	<keyword>Juxtarenal</keyword>
	<keyword>Pararenal</keyword>
	<keyword>Endovascular</keyword>
</DOC>